Targeting escape mutations
in hematological cancers
with first and best in class medicines
A small molecule oncology drug discovery company that is committed to defeating cancer.
Lomond Therapeutics, a precision hematology company, is the development stage spinout from Eilean Therapeutics - a biopharma targeting resistant mutation in hematological and solid cancer malignancies.
